Mutated Citrullinated Vimentin

from Wikipedia, the free encyclopedia

The detection of autoantibodies against mutated citrullinated vimentin (MCV) is a laboratory parameter for the diagnosis of rheumatoid arthritis (RA).

RA is an autoimmune disease. The detection of certain autoantibodies (these are antibodies against the body's own tissue) can support the doctor in diagnosing the disease and making therapy decisions. This is especially true for the early forms of RA when there are no typical symptoms (yet).

Basics

The citrullination of proteins is a physiological (i.e. naturally occurring in the body) process in which the amino acid arginine is enzymatically converted into the amino acid citrulline . The body's own protein, which is changed as a result, is viewed by the immune system as foreign, which leads to the formation of auto-reactive ("directed against itself") antibodies that attack the body's own tissue and trigger an inflammatory reaction. The result is an autoimmune disease .

Citrullinated proteins have been detected in the joints of patients with rheumatoid arthritis. One of these proteins is the mutated citrullinated vimentin (MCV), which is identical to the Sa antigen described in 1994.

The MCV antibodies are considered biomarkers for RA. The diagnostic and prognostic value of the MCV antibody detection is higher than that of the rheumatoid factors .

The citrullination of vimentin is essential to the development of RA. In addition, a connection between the MCV antibody concentration with disease activity and the severity of rheumatoid arthritis has been proven.

meaning

The medical benefit of the MCV antibody detection lies in the early appearance of these biomarkers and thus in the possibility of diagnosing the early forms of RA and treating the disease before the onset of pain and damage.

With the development of a point-of-care test that combines anti-MCV detection with the detection of rheumatoid factors and achieves a specificity of 99.7%, important advances have been made, especially in early diagnosis of rheumatism .

MCV antibodies are also important prognostic biomarkers for assessing the course of rheumatoid arthritis. There is also evidence of a connection between the MCV antibody concentration and the success of therapy in RA.

Individual evidence

  1. ↑ FC Arnett, SM Edworthy, DA Bloch, DJ McShane, JF Fries, NS Cooper, LA Healey, SR Kaplan, MH Liang, HS Luthra et al .: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis . In: Arthritis Rheum . , 1988 Mar, 31 (3), pp. 315-324, PMID 3358796
  2. ^ B György, E Tóth, E Tarcsa, A Falus, EI. Buzás: Citrullination: A posttranslational modification in health and disease . In: Int J Biochem Cell Biol. , 2006, 38 (10), pp. 1662-1677, Epub 2006 Mar 30. Review.
  3. ^ N Després, G Boire, FJ Lopez-Longo, HA. Ménard: The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis . In: J Rheumatol , 1994, 21, pp. 1027-1033, PMID 7932409
  4. ↑ Antibodies against mutated citrullinated vimentin (anti-MCV) in rheumatoid arthritis . (PDF; 246 kB)
  5. ↑ L Mathsson, M Mullazehi, MC Wick, O Sjoberg, VR van, L Klareskog et al .: Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value Concerning future radiographic progression as Compared with antibodies against cyclic citrullinated peptides . In: Arthritis Rheum , 2007, 58 (1), pp. 36-45, doi: 10.1002 / art.23188 .
  6. ↑ Renger F, Bang H, Fredenhagen G, Natusch A, Backhaus M, Feist E, Egerer K, Burmester GR: Anti-MCV Antibody Test for the Diagnosis of Rheumatoid Arthritis Using a POCT-Immunoassay Archived from the original on May 27, 2010. Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. In: # 1630, poster presentation 2008 Annual Scientific Meeting, American College of Rheumatology . August. Retrieved September 15, 2009. @1@ 2Template: Webachiv / IABot / acr.confex.com
  7. ↑ H Bang, K Egerer, A Gauliard, K Lüthke, PE Rudolph, G Fredenhagen et al .: Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis . In: Arthritis Rheum , 2007, 56 (8), pp. 2503-2511.
  8. ↑ Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, Odegard S, Uhlig T, Gaarder PI, Kvien TK: Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a ten-year prospective study . In: Ann Rheum Dis . . August. doi : 10.1136 / ard.2009.113092 .
  9. ^ PN Roland, SG Mignot, A Bruns, M Hurtado, E Palazzo, G Havem, P Dieudé, O Meyer, SC. Martin: Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy . In: Arthritis Res Ther . , 2008 Dec 10,10 (6), R142, doi: 10.1186 / ar2570 , arthritis-research.com